Meridian Bioscience Stock

Meridian Bioscience FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 173.69 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 67.99 % — a change of 155.44% (higher).

FCF Conversion

173.69 %

YoY

155.44%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Meridian Bioscience is 2026 173.69 % . FCF Conversion Rate (FCF/EBITDA) of Meridian Bioscience was 2025 67.99 % . It decreases by 155.44% higher compared to the previous year.

The Meridian Bioscience FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
107.18 USD
Jan 1, 2016
103.17 USD
Jan 1, 2017
170.79 USD
Jan 1, 2018
128.49 USD
Jan 1, 2019
132.70 USD
Jan 1, 2020
96.71 USD
Jan 1, 2021
67.99 USD
Jan 1, 2022
173.69 USD
The Meridian Bioscience FCF Conversion history
YEARFCF ConversionYoY
173.69 %+155.44%
67.99 %-29.69%
96.71 %-27.12%
132.70 %+3.28%
128.49 %-24.77%
170.79 %+65.54%
103.17 %-3.75%
107.18 %+18.98%
90.09 %
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

FCF Conversion Rate (FCF/EBITDA) of Meridian Bioscience is 173.69 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Meridian Bioscience changed from 67.99 % to 173.69 %, representing a 155.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Meridian Bioscience

All Key Metrics — Meridian Bioscience